LIVN

LivaNova PLC (LIVN) | Rumor.io

LivaNova

LIVN

Attention (50-day avg)0%

Attention rank (50-day avg)#4,044

Bullish sentiment (50-day avg)100%

Price to earnings ratio22.8

Market capitalization4.3B

Earnings per share3.39

Dividend yield (TTM)—

Revenue (annual)1.4B

Net income (annual)-242.5M

Social

What share of all stock conversation is about LIVN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.05% +0.05

May 6

LivaNova ($LIVN) reported Q1 2026 revenue of $362.3M, a 14.3% YoY increase, and adjusted EPS of $0.98.
The company raised its full-year 2026 guidance to 7-8% constant-currency revenue growth and adjusted diluted EPS to $4.20-$4.30.
LivaNova's Cardiopulmonary segment drove growth with an 18.3% increase, while the Neuromodulation segment grew 9.3% in Q1 2026.

Generated by AI

Sentiment

Of the messages about LIVN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	94.92% -2.44
Bearish	—	—	0% 0	5.08% +2.44

Bullish· Apr 5

LIVN is seen as a potentially lucrative investment opportunity, with the stock price expected to rebound and reach $80 in 2 months or less.
The company's low debt and strong sales of ~$1.1B make it an attractive long-term investment, with a market capitalization of ~$3.3B.
The stock is considered oversold and due for a significant price increase, with a target price of $75.00 and a predicted move of 5 points higher in 2 months.

Bearish· Apr 5

LivaNova's preliminary Q1 revenue missed analysts' estimates, with the company citing a changing competitive environment in the US.
The company's Neuromodulation business experienced unexpected weakness in the US, contributing to the revenue miss.
LivaNova's stock price has been declining, with a 28.5% move on the day, and has hit a new 52-week low.

Generated by AI

Topics

Of the messages about LIVN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	25%	20.59%
Announcements	—	—	25%	27.35%
Technical Analysis	—	—	50%	0.14%
Earnings	—	—	0%	4.07%
Controversies	—	—	0%	0.01%
Macro	—	—	0%	47.84%

Earnings· Feb 27

LivaNova PLC reported Q4 2018 earnings of $1.12, beating consensus estimates of $1.10 and Earnings Whisper estimates of $1.08.
CEO Damien McDonald discussed Q4 2018 results in an earnings call, noting increased sales despite a reported fourth-quarter loss.
LivaNova PLC updated FY19 earnings guidance to $3.55-3.75 EPS, below consensus estimates.

Analysts· Feb 24

LivaNova's price target was lowered to $106.00 by Needham & Company LLC.
UBS Group upgraded LivaNova to Buy from Neutral with a price target of $96.00.
Needham & Company LLC maintained a Buy rating for LivaNova but lowered its price target from $120.00 to $106.00.

Announcements· Oct 12

LivaNova's share price could potentially double according to Investor PrimeStone.
LivaNova confirms receipt of a letter from PrimeStone Capital, urging the company to shake up its business.
LivaNova presents new data at the European Association for Cardio-Thoracic Surgery Annual Meeting, demonstrating the benefits of its Perceval Sutureless Valve.

Generated by AI

Community

Of the messages about LIVN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	71.43%	0.03%
Newcomers	—	—	28.57%	99.97%

Regulars· Mar 20

LivaNova PLC traded 123% above average volume, with a 10.59% increase in the company's stock price.
LivaNova PLC's stock is performing better than the overall health care sector, with a 10.4% increase despite the sector's 0.7% decline.
LivaNova PLC announced a positive predictive outcome in its OSPREY clinical study for moderate to severe obstructive sleep apnea, a potential major breakthrough for the company.

Newcomers· May 6

Newcomers are focused on LivaNova's Q1 2026 earnings, which reported a 14.3% YoY revenue growth to $362.3M, exceeding expectations.
The company has raised its full-year 2026 revenue and adjusted EPS guidance due to strong Q1 results.
LivaNova's Aura6000 System has secured FDA premarket approval, providing a significant entry into the high-growth obstructive sleep apnea market.

Generated by AI

News

Operating Leverage and Product Innovation Drive LivaNova’s(LIVN) Sustained Profit Outlook

5d agoYahoo Finance

LivaNova Director Trades $273K In Company Stock

14d agoBenzinga

LivaNova at Morgan Stanley conference: growth plan leans on core units

15d agoInvesting.com

LivaNova Director Sells 1,650 Shares for $131,500 | The Motley Fool

The insider sold 1,650 shares but still retains nearly 8,000 shares.

19d agoThe Motley Fool

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

GLOUCESTER, England, September 03, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City:

26d agofinance.yahoo.com

Piper Sandler raises Livanova stock price target on cardiopulmonary growth outlook

27d agoInvesting.com

Also Discussed

Investors talking about LIVN also mention

#	Name	Attention
1	Global Business Travel Group, Inc.GBTG	0%new
2	LeMaitre Vascular Inc.LMAT	0%0
3	Capri Holdings Ltd.CPRI	0%new
4	Supernus Pharmaceuticals, Inc.SUPN	0%new
5	Assurant Inc.AIZ	0%0
6	Klaviyo Inc.KVYO	0%0
7	ANGI Homeservices IncANGI	0%0
8	Extreme Networks Inc.EXTR	0%new
9	Trupanion Inc.TRUP	0%0
10	Inter & Co. Inc. Class A Common SharesINTR	0%0

LivaNova PLC

Healthcare
Medical Devices

LivaNova PLC is a global medical technology company focused on designing, developing, manufacturing, and marketing therapies and devices for cardiac and neurological care. LivaNova PLC’s current business is organized around cardiopulmonary products, neuromodulation therapies, and advanced circulatory support, serving hospitals, clinicians, and healthcare systems with equipment used in cardiac surgery, temporary life support, and treatment of conditions such as drug-resistant epilepsy and difficult-to-treat depression. The company also provides related services and support for its medical devices, making it an important supplier in specialized hospital care and life-sustaining treatment settings. Headquartered in London, England, LivaNova PLC operates across international markets and plays a role in delivering targeted medical technologies for complex clinical needs.

Website

Location

5220 Valiant Court

Gloucester, GL3 4FE

United Kingdom

Social

What share of all stock conversation is about LIVN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.05% +0.05

May 6

LivaNova ($LIVN) reported Q1 2026 revenue of $362.3M, a 14.3% YoY increase, and adjusted EPS of $0.98.
The company raised its full-year 2026 guidance to 7-8% constant-currency revenue growth and adjusted diluted EPS to $4.20-$4.30.
LivaNova's Cardiopulmonary segment drove growth with an 18.3% increase, while the Neuromodulation segment grew 9.3% in Q1 2026.

Generated by AI

Sentiment

Of the messages about LIVN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	94.92% -2.44
Bearish	—	—	0% 0	5.08% +2.44

Bullish· Apr 5

LIVN is seen as a potentially lucrative investment opportunity, with the stock price expected to rebound and reach $80 in 2 months or less.
The company's low debt and strong sales of ~$1.1B make it an attractive long-term investment, with a market capitalization of ~$3.3B.
The stock is considered oversold and due for a significant price increase, with a target price of $75.00 and a predicted move of 5 points higher in 2 months.

Bearish· Apr 5

LivaNova's preliminary Q1 revenue missed analysts' estimates, with the company citing a changing competitive environment in the US.
The company's Neuromodulation business experienced unexpected weakness in the US, contributing to the revenue miss.
LivaNova's stock price has been declining, with a 28.5% move on the day, and has hit a new 52-week low.

Generated by AI

Topics

Of the messages about LIVN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	25%	20.59%
Announcements	—	—	25%	27.35%
Technical Analysis	—	—	50%	0.14%
Earnings	—	—	0%	4.07%
Controversies	—	—	0%	0.01%
Macro	—	—	0%	47.84%

Earnings· Feb 27

LivaNova PLC reported Q4 2018 earnings of $1.12, beating consensus estimates of $1.10 and Earnings Whisper estimates of $1.08.
CEO Damien McDonald discussed Q4 2018 results in an earnings call, noting increased sales despite a reported fourth-quarter loss.
LivaNova PLC updated FY19 earnings guidance to $3.55-3.75 EPS, below consensus estimates.

Analysts· Feb 24

LivaNova's price target was lowered to $106.00 by Needham & Company LLC.
UBS Group upgraded LivaNova to Buy from Neutral with a price target of $96.00.
Needham & Company LLC maintained a Buy rating for LivaNova but lowered its price target from $120.00 to $106.00.

Announcements· Oct 12

LivaNova's share price could potentially double according to Investor PrimeStone.
LivaNova confirms receipt of a letter from PrimeStone Capital, urging the company to shake up its business.
LivaNova presents new data at the European Association for Cardio-Thoracic Surgery Annual Meeting, demonstrating the benefits of its Perceval Sutureless Valve.

Generated by AI

Community

Of the messages about LIVN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	71.43%	0.03%
Newcomers	—	—	28.57%	99.97%

Regulars· Mar 20

LivaNova PLC traded 123% above average volume, with a 10.59% increase in the company's stock price.
LivaNova PLC's stock is performing better than the overall health care sector, with a 10.4% increase despite the sector's 0.7% decline.
LivaNova PLC announced a positive predictive outcome in its OSPREY clinical study for moderate to severe obstructive sleep apnea, a potential major breakthrough for the company.

Newcomers· May 6

Newcomers are focused on LivaNova's Q1 2026 earnings, which reported a 14.3% YoY revenue growth to $362.3M, exceeding expectations.
The company has raised its full-year 2026 revenue and adjusted EPS guidance due to strong Q1 results.
LivaNova's Aura6000 System has secured FDA premarket approval, providing a significant entry into the high-growth obstructive sleep apnea market.

Generated by AI

LivaNova

Social

May 6

Bullish· Apr 5

Bearish· Apr 5

Earnings· Feb 27

Analysts· Feb 24

Announcements· Oct 12

Regulars· Mar 20

Newcomers· May 6

Operating Leverage and Product Innovation Drive LivaNova’s(LIVN) Sustained Profit Outlook

LivaNova Director Trades $273K In Company Stock

LivaNova at Morgan Stanley conference: growth plan leans on core units

LivaNova Director Sells 1,650 Shares for $131,500 | The Motley Fool

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

Piper Sandler raises Livanova stock price target on cardiopulmonary growth outlook

Also Discussed

LivaNova PLC

Company Information

Location

Social

May 6

Bullish· Apr 5

Bearish· Apr 5

Earnings· Feb 27

Analysts· Feb 24

Announcements· Oct 12

Regulars· Mar 20

Newcomers· May 6

Operating Leverage and Product Innovation Drive LivaNova’s(LIVN) Sustained Profit Outlook

LivaNova Director Trades $273K In Company Stock

LivaNova at Morgan Stanley conference: growth plan leans on core units

LivaNova Director Sells 1,650 Shares for $131,500 | The Motley Fool

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

Piper Sandler raises Livanova stock price target on cardiopulmonary growth outlook

Also Discussed